DOSING REGIMEN OF A WNT INHIBITOR AND AN ANTI-PD-1 ANTIBODY MOLECULE IN A COMBINATION Russian patent published in 2022 - IPC A61K31/497 A61K39/395 A61P35/00 

FIELD: medicine; pharmaceutics.

SUBSTANCE: invention relates to a method of treating cancer involving administering a pharmaceutical combination containing (i) 2-(2',3-dimethyl-[2,4'-bipyridine]-5-yl)-N-(5-(pyrazine-2-)yl)pyridine-2-yl)acetamide or a pharmaceutically acceptable salt thereof and (ii) an anti-PD-1 antibody molecule selected from nivolumab, pembrolizumab, pidilizumab, PDR-001 or a pharmaceutically acceptable salt thereof; where (ii) is introduced at least once per cycle; where (i) is administered daily on days 1–15 or days 1–16 of each cycle for up to 4 cycles or (i) is introduced for days 1–8 of each cycle for up to 4 cycles; where each cycle is 28 days or 30 days; where the cancer is triple-negative breast cancer (TNBC), squamous cell carcinoma of the head and neck, pancreatic cancer, gastrointestinal cancer, colorectal cancer, squamous cell carcinoma of the lung, squamous cell carcinoma of the esophagus, squamous cell carcinoma of the cervix or melanoma.

EFFECT: invention provides solving the problem of developing new types of combination therapy of cancer, which activate the immune system or overcome resistance to types of immunotherapy.

13 cl, 11 dwg, 4 tbl, 5 ex